“CLIA-waived” point-of-care testing (POCT) is testing performed under a CLIA Certificate of Waiver — the lightest-touch of the five certificate types issued under the Clinical Laboratory Improvement Amendments (42 CFR Part 493). It covers tests the FDA has categorized as “waived” complexity: simple to use, with a low risk of an erroneous result causing patient harm. Glucose meters, rapid strep and flu/COVID-19 antigen tests, urine dipsticks, fingerstick hemoglobin A1c, and INR coagulation monitors are common examples. For background on the full certificate structure — Certificate of Waiver, Provider-Performed Microscopy (PPM), Registration, Compliance, and Accreditation — see our guide to CLIA certification. This page focuses on the operational and procurement questions specific to waived-status POCT: what the waiver actually authorizes, and what a buyer needs to verify before purchasing a device for a waived-testing site.
What a Certificate of Waiver actually authorizes
A site holding only a Certificate of Waiver may perform waived tests but is exempt from CLIA’s routine inspection, personnel-qualification, and proficiency-testing requirements that apply to moderate- and high-complexity testing. CMS or a state survey agency can still conduct unannounced validation or complaint-driven inspections of waived sites, and states may layer their own, stricter licensure requirements on top of CLIA — several states (including New York, California, and Maryland) require a state laboratory permit even for waived-only testing. The federal application is CMS-116, filed with the state CLIA agency, and the certificate is renewed on a two-year cycle with an associated fee.
The reduced federal oversight is exactly why waived testing has spread so widely into physician office labs, urgent care and retail clinics, pharmacies, employer health programs, school health offices, correctional facilities, and community or research-adjacent screening programs. It is also why the obligations that remain — even though CMS is not routinely checking them — are easy for a site to quietly drift out of compliance with, since nothing is inspecting day-to-day.
Waived status belongs to a specific device, not a general test category
This is the detail that matters most for procurement and is the one most often missed: a test is not waived in the abstract. The FDA grants waived status to a specific test system — a named manufacturer, model, and, in many cases, specimen type and configuration — not to “glucose testing” or “rapid antigen testing” as a category. Two devices that measure the same analyte can sit in different complexity categories, and a device that is waived for one specimen type (e.g., fingerstick capillary blood) may not be waived for another (e.g., venous blood) even though it reports the same result.
Before purchasing any device for a Certificate-of-Waiver site, procurement and lab-operations staff should confirm the exact model currently appears on the authoritative federal source: the FDA’s CLIA Categorizations database, which lists every test system’s current complexity category, or the CMS list of currently waived analytes. Waived-status listings do change — the FDA periodically reclassifies or adds test systems — so this is a check to repeat at time of purchase, not a fact to rely on from a prior procurement cycle or a manufacturer’s marketing material alone.
Why manufacturer instructions are the whole compliance model
Because a waived site isn’t undergoing routine proficiency testing or on-site complexity review, the entire quality assurance model for waived testing rests on one requirement: the test must be performed exactly as the manufacturer’s package insert specifies — the approved specimen type, storage conditions, run procedure, and quality-control schedule. Deviating from the labeled instructions (an off-label specimen type, a modified dilution or run protocol, use past the labeled shelf life, or substituting reagents not specified by the manufacturer) can void the test’s waived status. If that happens, the site is legally performing a moderate- or high-complexity test without the certificate, personnel qualifications, or proficiency-testing enrollment that complexity level requires — a real exposure that a facility can accumulate for months before it surfaces, precisely because waived sites aren’t routinely inspected.
For procurement specifically, this means the buying decision doesn’t end at confirming waived status. It also has to confirm the device’s labeled specimen type and intended use match how the site actually intends to use it, and that staff will be trained to the manufacturer’s current package insert rather than a prior version or an informal in-house adaptation.
A procurement checklist for CLIA-waived POCT devices
- Confirm current waived status for the exact model and specimen type against the FDA CLIA Categorizations database at the time of purchase, not from a previous cycle’s records.
- Match the labeled specimen type and use case to the actual clinical/testing workflow at the site — fingerstick vs. venous, nasal vs. nasopharyngeal, and so on.
- Verify the site’s Certificate of Waiver is current and, where applicable, that state licensure covers the specific test being added.
- Confirm manufacturer-required quality-control materials and frequency are budgeted and available — waived status removes CLIA’s proficiency-testing mandate but not the manufacturer’s own QC instructions.
- Check vendor support for staff training on the current package insert and plan for retraining whenever the manufacturer updates instructions.
- Confirm recordkeeping capability for QC logs, lot numbers, and result records; most states require these be retained for a minimum period even for waived testing, and retention requirements can exceed the federal floor.
These procurement fundamentals sit alongside the site’s broader supplier-qualification process; see our guides to the vendor qualification process and supplier audits for how a lab or clinical procurement function typically documents and repeats these checks across its device vendors.
Waived testing and proficiency testing
CLIA does not require sites to enroll waived tests in a CMS-approved proficiency testing (PT) program the way it does for moderate- and high-complexity testing. Many waived-testing sites nonetheless choose to run periodic internal or external accuracy checks voluntarily, both as good practice and because payers, accreditors, or state regulators sometimes expect it. For the formal PT/EQA framework that applies once a facility holds a higher-complexity certificate, see proficiency testing and external quality assessment.
Frequently asked questions
What is a CLIA Certificate of Waiver?
It’s one of five CLIA certificate types, authorizing a site to perform only tests the FDA has categorized as waived complexity. It carries minimal routine federal oversight compared to the certificates required for moderate- or high-complexity testing, but the site must still apply (CMS-116), pay a renewal fee every two years, and follow manufacturer test instructions exactly.
Do CLIA-waived tests require proficiency testing?
No federal PT enrollment is required for waived tests under CLIA, unlike moderate- and high-complexity testing. Some sites run voluntary accuracy checks anyway, and state or accreditor requirements can differ from the federal floor.
Can any glucose meter (or similar device) be used for CLIA-waived testing?
No. Waived status attaches to a specific manufacturer model and, often, a specific specimen type — not to glucose testing as a category. The exact device and configuration has to appear on the FDA’s current CLIA Categorizations list before it can be used under a Certificate of Waiver.
What happens if a site modifies how it runs a waived test?
Any deviation from the manufacturer’s labeled instructions — a different specimen type, altered procedure, or unapproved reagent — can void the test’s waived classification. The site would then be performing a higher-complexity test without the certificate, personnel qualifications, or proficiency testing that level requires.
How do I check whether a POCT device is currently CLIA-waived?
Check the FDA’s CLIA Categorizations database for the specific manufacturer and model before purchase; waived-status listings are updated as the FDA reviews and reclassifies test systems, so a prior procurement cycle’s list shouldn’t be assumed current.
